Browse by author
Lookup NU author(s): Dr Tina Biss,
Dr Mark Velangi,
Dr John Hanley
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
We report the use of rituximab (MabThera((R)); Roche Grenzach-Wyhlen, Germany) in a 6-year-old boy with severe haemophilia A and a high titre alloimmune factor VIII (FVIII) antibody, which had failed to respond to standard immune tolerance therapy. Rituximab was administered in 4 weekly doses with concurrent high-dose i.v. immunoglobulin (Flebogamma((R)); Grifols, Barcelona, Spain) followed by daily high-dose recombinant FVIII concentrate (Recombinate((R)); Baxter, CA, USA). Despite a fall in CD20 positive cell count to undetectable levels the inhibitor persisted. We discuss the possible reasons for failure of immune tolerance induction and review the literature concerning the use of rituximab for this indication.
Author(s): Biss TT, Velangi MR, Hanley JP
Publication type: Article
Publication status: Published
ISSN (print): 1351-8216
ISSN (electronic): 1365-2516
Publisher: Wiley-Blackwell Publishing Ltd.
Altmetrics provided by Altmetric